Estrogen receptor alpha polymorphisms: Correlation with clinicopathological parameters in breast cancer

Neoplasma

Volumn 57, Issue 4, 2010, Pages 306-315

  Anghel, A ^a   Raica, M ^a   Narita, D ^a   Seclaman, E ^a   Nicola, T ^a   Ursoniu, S ^a   Anghel, M ^a   Popovici, E ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Breast cancer; Estrogen receptor alpha gene; Single nucleotide polymorphisms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; DNA; ESR1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; BODY MASS; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA HYBRIDIZATION; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77955284712     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_04_306     Document Type: Article

References (51)

1. DUNNING HORNER MJ, RIES LAG, KRAPCHO M, NEYMAN N, AMINOU R, et al. SEER Cancer Statistics Review 2009; National Cancer Institute. Bethesda, MD, http://seer. cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site.
2. DUNNING AM, HEALEY CS, PHAROAH PD, TEARE MD, PONDER BA, EASTON DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8: 843-854.
3. PHAROAH PD, ANTONIOU AC, EASTON DF, PONDER BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-2803. doi:10.1056/ NEJMsa0708739
4. RIPPERGER T, GADZICKI, MEINDL A, SCHLEGELBERGER B. Breast cancer susceptibility: current knowledge and implications for genetic counseling. Eu J Human Genetics 2009; 17: 722-731. doi:10.1038/ejhg.2008.212
5. PHAROAH PD, TYRER J, DUNNING AM, EASTON DF, PONDER BAJ, SEARCH Investigators. Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 2007; 3: e 42.
6. GOLD B, KIRCHHOFF T, STEFANOV S. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. PNAS 2008; 105: 4340-4345. doi:10.1073/ pnas.0800441105
7. EASTON DF, POOLEY KA, DUNNING AM. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093. doi:10.1038/nature05887
8. BAYNES C, HEALEY CS, POOLEY CA, SCOLLEN S, LUBEN RN et al. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlike to increase breast cancer risk. Breast Cancer Res 2007; 9: R27. doi:10.1186/bcr1669
9. KININIS M AND KRAUS WL. A global view of transcriptional regulation by nuclear receptors: gene expression, factor localization and DNA sequence analysis. Nuclear Receptor Signaling 2008; 6: e005.
10. BJORNSTROM L AND SJOBERG M. Mechanisms of estrogen receptor signaling: converge of genomic and nongenomic actions on target genes. Mol Endocrinology 2005; 19: 833-842. doi:10.1210/me.2004-0486
11. GENNARI L, MERLOTTI D, DE PAOLA V, CALABRÒ A, BECHERINI L et al. Estrogen Receptor Gene polymorphisms and the genetics of osteoporosis: a HuGE Review. Am J Epidemiol 2005; 161: 307-320. doi:10.1093/aje/kwi055
12. DEROO BJ and KORACH KS. Estrogen receptors and human disease. J Clin Invest 2006; 116: 561-570. doi:10.1172/ JCI27987
13. YUAN HY, CHIOU JJ, TSENG WH, LIU CH, LIU CK et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006; 34 (Web Server issue): W635-641.
14. CONDE L, VAQUERIZAS JM, DOPAZO H, ARBIZA L, REUMERS J et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res 2006; 34 (Web Server issue): W621-625.
15. ELSTON CW, ELLIS IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410. doi:10.1111/j.1365-2559.1991. tb00229.x
16. NARITA D, CIMPEAN A, ANGHEL A, RAICA M. Prostatespecific antigen value as a marker in breast cancer. Neoplasma 2006; 2: 161-167.
17. ELLIS I O, DOWSETT M, BARTLETT J, WALKER R, COOKE T. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: 890-892. doi:10.1136/jcp.53.12.890
18. RAYMOND M. AND ROUSSET F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Heredity 1995; 86: 248-249.
19. GAUNT TR, RODRIGUEZ S, DAY INM. Cubic exact solutions for the estimation of pair-wise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 2007; 8: 428-437. doi:10.1186/1471-2105-8-428
20. RAVDIN PM, SIMINOFF LA, DAVIS GJ, MERCER MB, HEWLETT J et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
21. INTERNATIONAL HAPMAP CONSORTIUM, FRAZER KA, BALLINGER DG, COX DR, HINDS DA, STUVE LL et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-861. doi:10.1038/nature06258
22. DENG G, ZHOU G, ZHAI Y, LI S, LI X et al. Association of Estrogen Receptor Alpha polymorphisms with Susceptibility to Chronic Hepatitis B Virus Infection. Hepatology 2004; 40: 318-326. doi:10.1002/hep.20318
23. NILSSON M, DAHLMANN I, JIAO H, GUSTAFSSON JA, ARNER P, DAHLMAN-WRIGHT K. Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis-a cohort study. BMC Medical Genetics 2007; 8: 73-85. doi:10.1186/1471-2350-8-73
24. ZOFKOVÁ I, ZAJÍCKOVÁ K. The estrogen receptor alpha gene determines serum androstenedione levels in postmenopausal women. Steroids 2002; 67: 815-819. doi:10.1016/S0039-128X(02)00034-X
25. HERRINGTON DM, HOWARD TD, HAWKINS GA. Estrogen-receptor polymorphism and effects of estrogen replacement therapy on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346: 967-974. doi:10.1056/NEJMoa012952
26. LONG JR, XU H, ZHAO LJ, LIU PY, SHEN H et al. The estrogen receptor α gene is linked and/or associated with age of menarche in different ethnic groups. J Med Genet 2005; 42: 796-800. doi:10.1136/jmg.2004.028381
27. ZUPPAN PJ. Polymorphisms at the estrogen receptor locus and linkage relationships on chromosome 6q. Cytogenet Cell Genet 1989; 51: 1116-1120.
28. YAICH L, DUPONT WD, CAVENER DR AND PARL FF. Analysis of the PvuII Restriction Fragment-length Polymorphism and Exon Structure of the Estrogen Receptor Gene in Breast Cancer and Peripheral Blood. Cancer Res 1992; 52: 77-83.
29. JAKIMIUK AJ, NOWICKA M, BOGUSIEWICZ M, ADAMIAK A, SKORUPSKI P et al. Prevalence of estrogen receptor α PvuII and XbaI polymorphism in population of Polish postmenopausal women. Folia Histochem et cytobiol 2007; 45: 331-338.
30. BOYAPATI SM, SHU XO, RUAN ZX, CAI Q, SMITH JR et al. Polymorphisms in ER-α gene interact with estrogen receptor status in breast cancer survival. Clin Cancer Res 2005; 11:1093-1098.
31. MORET-ONLAND CN, VAN GILS CH, ROEST M, GROBBEE DE, PEETERS PHM. The estrogen receptor α gene and breast cancer risk (The Netherlands). Cancer Causes and Control 2005; 16: 1195-1202.
32. GONZALEZ-ZULOETA LADD AM, VASQUEZ AA, RIVADENEIRA F, SIEMES C, HOFMAN A et al. Estrogen receptor α polymorphisms and postmenopausal breast cancer risk. Breast Cancer Res Treat 2008; 107: 415-419. doi:10.1007/ s10549-007-9562-3
33. WEDREN S, LOVMAR L, HUMPHREYS K, MAGNUSSON C, MELHUS H et al. Estrogen receptor α gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004; 6: R437-R449. doi:10.1186/bcr811
34. ANDERSON TI, HEIMDAL KR, SKREDE M, TVEIT K, BERG K AND BØRRESEN AL. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 2004; 94: 665-670.
35. SHIN A, KANG D, NISHIO H, LEE MJ, PARK SK et al. Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 2003; 80: 127-131. doi:10.1023/ A:1024439202528
36. CAI Q, SHU XO, JIN F, DAI Q, WEN W et al. Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev 2003; 12: 853-859.
37. TAPPER W, HAMMOND V, GERTY S, ENNIS S, SIMMONDS P, COLLINS A, THE PROSPECTIVE STUDY OF OUTCOMES IN SPORADIC VERSUS HEREDITARY BREAST CANCER (POSH) STEERING GROUP and DIANA ECCLES. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 2008; 10: R108-R118.
38. EINARSDOTTIR K, DARABI H, Li Y, LOW YL, LI YQ et al. ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 2008; 10: R15-R24. doi:10.1186/bcr1861
39. HSIAO WC, YOUNG KC, LIN SL, LIN PW. Estrogen receptor-α polymorphism in Taiwanese clinical breast cancer population: a case-control study. Breast Cancer Res 2004; 6: 180-186. doi:10.1186/bcr770
40. IWASE H & KOBAYASHI S. Alterations and polymorphisms of the estrogen receptor gene in breast cancer. Breast Cancer 1997; 4: 57-66. doi:10.1007/BF02967058
41. ROODI N, BAILEY LR, KAO WY, VERRIER CS, YEE CJ et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995; 87: 446-451. doi:10.1093/jnci/87.6.446
42. VASCONCELOS A, MEDEIROS R, VEIGA I, PEREIRA D, CARRILHO S et al. Analysis of Estrogen Receptor Polymorphism in Codon 325 by PCR-SSCP in Breast Cancer: Association with lymph node metastasis. Breast J 2002; 8: 226-229. doi:10.1046/j.1524-4741.2002.08407.x
43. SOUTHEY MC, BATTEN LE, MCCREDIE MR, GILES GG, DITE G et al. Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. J Nat Cancer Inst 1998; 90: 532-536. doi:10.1093/jnci/90.7.532
44. GALLICHIO L, BERNDT S, MCSORLEY MA, NEWSCHAFFER CJ, THUITA LW et al. Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer 2006; 6: 173-184. doi:10.1186/1471-2407-6-173
45. GOLD B, KALUSH F, BERGERON J, SCOTT K, MITRA N et al. Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 2004; 64: 8891-8900. doi:10.1158/0008-5472.CAN-04-1256
46. WANG J, HIGUCHI R, MODUGNO F, LI J, UMBLAS N et al. Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res and Treat 2007; 106: 273-280. doi:10.1007/s10549-007-9497-8
47. YANG J, SINGLETON DW, SHAUGHNESSY EA, KHAN SA. The F-domain of estrogen receptor-alpha inhibits ligand induced receptor dimerization. Mol Cell Endocrinol 2008; 295: 94-100. doi:10.1016/j.mce.2008.08.001
48. VENABLES JP. Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647-7654. doi:10.1158/0008-5472. CAN-04-1910
49. SHI J, HU Z, PABON K, SCOTTO KW. Caffeine regulates alternative splicing in a subset of cancer-associated genes: A role for SC35. Mol Cell Biol 2008; 28: 883-895. doi:10.1128/ MCB.01345-07
50. LIN S, COUTINHO-MANSFIELD G, WANG D, PANDIT S, FU X-D. The splicing factor SC35 has an active role in transcriptional elongation. Nat Struct&Mol Biol 2008; 15: 819-826. doi:10.1038/nsmb.1461
51. LONG JR, ZHAO LJ, LIU PY, LU Y, DVORNYK V et al. Pattern of linkage disequilibrium and haplotype distribution in disease candidate genes. BMC Genetics 2004; 5: 11-18. doi:10.1186/1471-2156-5-11